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Serotonin1A receptors are important neurotransmitter receptors and belong to the superfamily
of G-protein coupled receptors (GPCRs). Although it is an important drug target, the crystal
structure of the serotonin1A receptor has not been solved yet. Earlier homology models of the
serotonin1A receptor were generated using rhodopsin as a template. We have used two recent
crystal structures of the human b2-adrenergic receptor, one of which shows specific cholesterol
binding site(s), as templates to model the human serotonin1A receptor. Since the sequence
similarity between the serotonin1A receptor and b2-adrenergic receptor is considerably higher than
the similarity between the serotonin1A receptor and rhodopsin, our model is more reliable.
Based on these templates, we generated models of the serotonin1A receptor in the absence and
presence of cholesterol. The receptor model appears more compact in the presence of cholesterol.
We validated the stability of ‘compactness’ using coarse-grain MD simulation. Importantly, all
ligands exhibit higher binding energies when docked to the receptor in the presence of cholesterol,
thereby implying that membrane cholesterol facilitates ligand binding to the serotonin1A receptor.
To the best of our knowledge, this is one of the first reports in which lipid-specific receptor
conformations have been modeled by homology modeling.
Introduction
The G-protein coupled receptor (GPCR) superfamily is the
largest and most diverse protein family in mammals, involved
in signal transduction across membranes.1–3 Cellular signaling
by GPCRs involves their activation by ligands present in the
extracellular environment and subsequent transduction of
signals to cellular interior through concerted changes in their
transmembrane domain structure.4 GPCRs are prototypical
members of the family of seven transmembrane domain
proteins and include >800 members which together constitute
B5% of the human genome.5 They dictate physiological
responses to a diverse array of stimuli that include endogenous
ligands such as biogenic amines, peptides, glycoproteins,
lipids, nucleotides, Ca2+ ions and various exogenous ligands
for sensory perceptions such as odorants, pheromones, and
even photons. As a consequence, these receptors mediate
multiple physiological processes such as neurotransmission,
secretion, cellular differentiation, growth, inflammatory and
immune responses. It is therefore only natural that GPCRs have
emerged as major targets for the development of novel drug
candidates in all clinical areas.6–10 Interestingly, althoughGPCRs
represent 30–50% of current drug targets, only a small fraction
of all GPCRs are presently targeted by drugs.11 This raises the
exciting possibility that receptors that are not yet recognized
could be potential drug targets for diseases that are difficult to
treat by currently available drugs. In spite of an enormous
interest in GPCR drug design owing to the pharmacological
significance of GPCRs, lack of three-dimensional structural
information severely limits GPCR drug design.12
Membrane proteins are difficult to crystallize in their native
conditions due to the intrinsic dependence on surrounding
membrane lipids.13 Since a significant portion of any integral
membrane protein (such as GPCRs) remains in contact with
the membrane lipid environment,14 membrane lipids are
necessary to maintain their structure and function. Purification
and crystallization of membrane proteins therefore continue to
be challenging in contemporary biology. Crystallization of
GPCRs is even more challenging due to the intrinsic structural
flexibility (particularly of the loop regions) giving rise to
multiple conformational states (conformational heterogeneity).15
High-resolution structural information of GPCRs is lacking
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for this reason. Crystal structures of only four GPCRs have been
solved with atomic resolution to date.16–19 Due to improved
resolution of modern-day crystallography, some of the solved
GPCR crystal structures reveal membrane lipids bound in close
proximity to the protein, indicating specific interactions of these
proteins with surrounding lipids17,20,21 (recently reviewed in
ref. 22). Since the crystallization of GPCRs poses considerable
challenges, in silico approaches for prediction of GPCR
structures are being increasingly used for structure-based drug
design.12,23–25 Homology modeling is a widely used approach in
which a known structure of a homologous receptor is used as a
template for model building. It is based on the concept that
three-dimensional structures of proteins are generally more
conserved than their amino acid sequences.26 As a result of this,
proteins with homologous sequences are expected to show
similar three-dimensional structures.
The serotonin1A (5-HT1A) receptor is an important neuro-
transmitter receptor and belongs to the superfamily of the seven
transmembrane domain GPCRs. It is the most extensively
studied of the serotonin receptors for a number of reasons.27,28
Serotonin receptors have been classified into at least 14 subtypes
on the basis of their pharmacological responses to specific
ligands, sequence similarities at the gene and amino acid levels,
gene organization, and second messenger coupling pathways.29
Serotonin1A receptors are known to play a key role in the
generation and modulation of various cognitive, developmental
and behavioral functions. Agonists and antagonists of the
serotonin1A receptor have been shown to possess potential
therapeutic effects in anxiety- or stress-related disorders.27 As a
result, the serotonin1A receptor serves as an important target in
the development of therapeutic agents for neuropsychiatric
disorders such as anxiety and depression. Interestingly, mutant
(knockout) mice lacking the serotonin1A receptor exhibit
enhanced anxiety-related behavior, and represent an important
animal model for genetic vulnerability to complex traits such as
anxiety disorders and aggression in higher animals.30,31 Taken
together, these results suggest that the serotonin1A receptor is a
central player in a multitude of physiological processes, and
represents an important drug target.
In this work, we have used two recent crystal structures of
the human b2-adrenergic receptor
17,21 as templates to model
the human serotonin1A receptor. One of these structures shows
specific cholesterol binding site(s) in the receptor.21 Based
on these templates, we generated molecular models of the
serotonin1A receptor in the absence and presence of cholesterol.
The receptor model appears more compact in presence of
cholesterol. We validated the stability of ‘compactness’ using
coarse-grainMD simulations. We have further used these models
to dock agonists and antagonists to the serotonin1A receptor, in
order to identify the role of membrane cholesterol in ligand
binding to the receptor. Our results show that the presence of
membrane cholesterol facilitates ligand binding to human
serotonin1A receptors. To the best of our knowledge, our results
represent one of the first reports in which lipid-specific receptor
conformations have been modeled by homology modeling.
Results
Sequence alignment and analysis
Human serotonin-1 receptors are divided into five classes which
include 1A, 1B, 1D, 1E and 1F subtypes. The serotonin1A
receptor is an important member of the serotonin-1 subfamily
and is estimated to have differentiated B650 million years ago
from the subfamily during the period when vertebrates diverged
from invertebrates.32,33 The human gene for the receptor encodes
a protein of 422 amino acids. Considering the presence of three
consensus sequences for N-linked glycosylation in the amino
terminus, and the homology of the receptor with b-adrenergic
receptor, it is predicted that the receptor is oriented in the plasma
membrane with the amino terminus facing the extracellular
region and the carboxy terminus facing the intracellular
cytoplasmic region.27,28,34 The transmembrane domains (I–VII)
of the receptor are connected by hydrophilic sequences of three
extracellular loops (EC1, EC2, EC3) and three intracellular loops
(IC1, IC2, IC3). Such an arrangement is typical for the G-protein
coupled receptor superfamily.35
A striking feature of the serotonin1A receptor is the length
(B120 residues spanning from 219–343 residues, based on
transmembrane helix prediction using TMHMM222) of its
third intracellular (IC3) loop. The IC3 loop of the serotonin1A
receptor is considerably longer than the corresponding loop of
Fig. 1 Sequence alignment of human serotonin-1 receptors. Human serotonin-1 receptor sequences that include receptors of five subclasses
(A, B and D–F) have been used for comparison. The amino acid Asn386, crucial for pindolol binding, is highlighted. See text for more details.
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other members of the serotonin-1 receptor subfamily (see Fig. 1)
and is important for coupling to G-proteins. Interestingly, it
has been previously reported using site-directed mutagenesis
that mutations in IC3 loop of the serotonin1A receptor alter
G-protein coupling from Gi to Gs in a ligand-dependent
manner.36 The serotonin1A receptor was the first of all types
of serotonin receptors to be cloned as an intronless genomic
clone (G-21) of the human genome, which cross-hybridized
with a full length b-adrenergic receptor probe at reduced
stringency.27,37 Sequence analysis of this genomic clone (later
identified as the serotonin1A receptor gene) shows B48%
amino acid similarity with the b2-adrenergic receptor in the
transmembrane region. A unique pharmacological feature of
the serotonin1A receptor is its affinity for the class of drugs
called b-blockers.38 Interestingly, sequence alignment of all
serotonin-1 receptors shows that Asn386 is present only in the
serotonin1A receptor (see Fig. 1), and is also found in
b-adrenergic receptors. Importantly, Asn386 is the residue that
is involved in the binding of pindolol, a b-blocker (and an
antagonist for b-adrenergic receptor).38 The serotonin1A
receptor was initially discovered as an ‘orphan’ receptor and
was identified (‘deorphanized’) later.39 The sequence alignment
of serotonin1A receptors from vertebrates and invertebrates is
shown in Fig. S1 and S2w. These figures show that the
sequence of serotonin1A receptors is predominantly conserved
from fish to humans, while the conservation among sequences
of invertebrates is rather poor.
Generation of molecular models of human serotonin1A receptors
As mentioned above, the overall sequence similarity of the
human serotonin1A receptor with the human b2-adrenergic
receptor isB48% in the transmembrane region. Fig. 2 shows
sequences of the template and human serotonin1A receptor to
show that the transmembrane regions are predominantly
conserved. The homologymodel generated by using b2-adrenergic
receptor as template would therefore be more reliable in the
transmembrane region. Modeling the transmembrane region
assumes significance since the ligand binding pockets of
serotonin1A receptors are believed to be present in the
transmembrane region.27 We therefore chose to focus mainly
on the transmembrane region of the receptor for further
analysis. We used two recently published structures of the
human b2-adrenergic receptor as templates. One of the structures
(PDB 2RH1)17 was used to generate the model in the absence
of cholesterol. The other structure (PDB 3D4S)21 exhibits
bound cholesterol molecules at the Consensus Cholesterol
binding Motif (CCM) in between the helices of a monomer.
We used the latter structure to generate a model of the
serotonin1A receptor in the presence of cholesterol. The
3D4S structure shows a cholesterol binding site between
transmembrane helices I–IV with two cholesterol molecules
bound per receptor monomer. The cholesterol binding site
appears to be characterized by the presence of a cleft located at
the membrane interfacial region.21 Both cholesterol molecules
bind in a shallow surface groove formed by segments of the
above-mentioned helices (I–IV), thereby providing an increase
in the intramolecular occluded surface area, a parameter often
correlated to the enhanced thermal stability of proteins.40
Importantly, we have earlier reported that cholesterol binding
sites are inherent characteristic features of serotonin1A
receptors and are conserved over natural evolution.22
The energy-minimized homology models of the human
serotonin1A receptor in the absence and presence of cholesterol
are shown in Fig. 3. These models were validated using
PROCHECK and WHAT IF servers. The corresponding
Ramachandran plots for receptor models in the absence and
presence of cholesterol are shown in Fig. 4. Analysis using
PROCHECK reveals that >98% of the residues are in overall
allowed regions (B91% in most favored regions and 8% in
additional allowed regions) in case of the model generated
without cholesterol (see Fig. 4a). Fig. 4b shows that in case of
the model in presence of cholesterol, >98% of the residues are
in overall allowed regions (B89% in most favored regions and
9% in additional allowed regions). In addition, models of the
serotonin1A receptor in the absence and presence of cholesterol
were validated using the ProSA program (Fig. S3w).
Importantly, Fig. 3 shows that the model of the serotonin1A
receptor in presence of cholesterol is more compact compared
to the model generated in absence of cholesterol. The presence
of cholesterol appears to increase the packing of the trans-
membrane helices. In this context, it is worth mentioning here
that calculation of packing values of various helices in the
b2-adrenergic receptor that are involved in the cholesterol
interaction site show that the packing of transmembrane
helices II and IV increases upon cholesterol binding. The
increased packing would restrict their mobility rendering
greater thermal stability to the protein.21 Our results from
homology modeling of the serotonin1A receptor in the
presence of cholesterol is in general agreement with these
results with the b2-adrenergic receptor. Interestingly, we have
recently observed that the thermal stability of the serotonin1A
receptor is enhanced in the presence of cholesterol.41
Validation of the compactness of the receptor model in the
presence of cholesterol by MD simulation
Models of the serotonin1A receptor in the absence and presence
of cholesterol, mapped to their coarse-grain representations,
Fig. 2 The final alignment used for modeling the human serotonin1A
receptor. Transmembrane helices are highlighted for easy identification.
The alignment shows that amino acid residues in transmembrane
helices are largely conserved.
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were simulated in 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC) and POPC-cholesterol bilayers, respectively.
Simulations of 8 ms were performed for both models. To test
the integrity of the models, they were compared to the starting
structures. The RMSD of the backbone beads of the trans-
membrane helices of the receptor in the absence and presence
of cholesterol is 0.3 nm and 0.5 nm, respectively. Importantly,
the volume of transmembrane domains (considering only the
backbone) of receptor models in the absence (11.6  0.005 nm3)
and presence (11.7  0.01 nm3) of cholesterol is comparable
and remains constant during the simulation (see Fig. 5).
In addition, the volume of transmembrane domains of the
receptor models in the absence (24.3  0.001 nm3) and
presence (24.7  0.04 nm3) of cholesterol is similar, even if
side chains are included (Fig. 5).
The deviation of the model of the serotonin1A receptor in
the absence of cholesterol from its starting conformation is
quite low (indicated by RMSD). The deviation of the model of
the serotonin1A receptor in the presence of cholesterol is
relatively high but within the average deviation, for coarse-grain
protein structures.42 During the simulation, a small repositioning
of helix II was observed when the receptor model was simulated
in the presence of cholesterol. We speculate that this deviation
is due to the absence of optimal packing of cholesterol
molecules in the starting structure since they were placed
randomly in the POPC bilayer. Nonetheless, the volume of
the receptor models remains constant, thereby ruling out any
substantial deviation of the transmembrane helices from their
modeled positions. In addition, the volume of both receptor
models is comparable, indicating that the ‘compactness’ of the
receptor model in the presence of cholesterol is not due to an
overall decrease in volume, but rather due to better packing of
the side chains resulting in a more compact lumen.
Analysis of molecular docking
Our understanding of the structure of the ligand binding site
of GPCRs at the atomic level is still emerging.43 Although the
crystal structure of the serotonin1A receptor has not been
worked out yet, mutagenesis studies have provided useful
insight in identifying amino acid residues important for ligand
binding and G-protein coupling of the receptor (reviewed in
ref. 27). In order to identify residues potentially involved
in ligand binding, seven ligands (three agonists and four
antagonists) were docked to the receptor in the absence and
presence of cholesterol. The agonists used were serotonin,
8-hydroxy-2(di-N-propylamino)tetralin (8-OH-DPAT) and
5-carboxamidotryptamine (5-CT) and their chemical structures
are shown in Fig. 6. The antagonists used were
4-(20-methoxy)-phenyl-1-[20-(N-20 0-pyridinyl)-p-fluorobenzamido]-
ethyl-piperazine (p-MPPF), N-(2-(1-(4-(2-methoxyphenyl)-
piperazinyl)-N-(2-pyridinyl)ethyl))cyclohexanecarboxamide
(WAY-100635), O-desmethyl derivative of WAY (DWAY)
and pyridinyl N-oxide derivative of WAY (NOWAY) and
their chemical structures are shown in Fig. 7. DWAY and
NOWAY have been shown to exhibit high affinity toward the
serotonin1A receptor.
44 The selective agonist 8-OH-DPAT was
the first compound that did not contain an indole nucleus as
part of its structure.44 The availability of 8-OH-DPAT helped
in the characterization of the serotonin1A receptor, thereby
making this receptor the most studied amongst serotonin
receptors.27 Serotonin is the natural ligand of the receptor.
Fig. 3 Energy-minimized final models of the human serotonin1A receptor in the absence (a) and presence (b) of cholesterol. Transmembrane
helices I–VII are shown in different colors. Panel (b) shows two cholesterol (yellow) molecules bound to the receptor. The receptor model in
presence of cholesterol appears more compact (see text).
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5-CT has been reported to display affinity similar to that of
serotonin.44
Fig. 8 shows the representative docked poses of these
ligands to the receptor. The docked poses of ligands to the
receptor are the best-energy solutions in the most populated
cluster. Clustering analysis with RMSD is shown in Fig. S4w.
Fig. 4 Ramachandran plots calculated for the human serotonin1A receptor models generated using PROCHECK server. Panels (a) and (b) show
Ramachandran plots for models generated in the absence and presence of cholesterol. Fully allowed and partially allowed regions are shown in red
and deep yellow, respectively. The analyzed results are shown along with the plots. A vast majority of amino acid residues (>98%) are within most
favored and partially allowed regions in both cases. See the Experimental section for other details.
Fig. 5 Plot of volume of transmembrane domains of serotonin1A
receptor models in the absence (red) and presence (green) of cholesterol
with simulation time. Lower two data sets correspond to the volume of
only the backbone, while the upper two traces correspond to volume
including side chains.
Fig. 6 Chemical structures of agonists for the serotonin1A receptor.
Agonists such as serotonin, 8-OH-DPAT and 5-CT are used to dock
to the receptor.
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The docked poses are depicted with the receptor in the absence
of cholesterol. Although the docked site remains largely
invariant in the presence of cholesterol, the predicted binding
energies differ (see later). Docked poses of serotonin and
WAY-100635 clearly show that the antagonist binding pocket
is relatively shallow compared to the agonist binding pocket.
Interestingly, it was previously suggested by us that the
antagonist binding site in the receptor could be at a relatively
shallow location compared to the agonist binding site.45 This
prediction was based on the effect of ethanol on the extent of
ligand binding of the receptor.
Although there is no structural data for the serotonin1A
receptor, there is considerable experimental data suggesting
possible ligand binding sites in the receptor. Site-directed
mutagenesis provides a powerful approach to identify the
location of the binding pocket in the receptor. Results
obtained from point mutations suggest that Asp82 and
Asp116 in transmembrane helices II and III are crucial for
binding of serotonin to the receptor.46 It has been suggested
that the carboxylate group in Asp82 and/or Asp116 probably
acts as a counter-ion to the amine group of serotonin, thereby
stabilizing its interaction.27 Interestingly, while Asp82 is
conserved in all cloned GPCRs, Asp116 is conserved only in
GPCRs that bind biogenic amines. Another possibility for
agonist binding is an interaction between a hydrogen bonding
group (e.g., hydroxyl group) of serotonin and the hydroxyl
group of serine or threonine residues. In addition, agonist
binding could be stabilized by aromatic p–p interactions with
the surrounding residues.44 Fig. 9 and 10 illustrate agonist and
antagonist docking poses on the serotonin1A receptor, and
Tables 1 and 2 show amino acid residues of the receptor
involved in interactions with ligands. The predicted binding
mode of serotonin shows hydrogen bonding with Asp116.
Fig. 11 shows the respective predicted binding energy of
ligands to the serotonin1A receptor in the absence and presence
of cholesterol. Higher binding energy implies better docking of
the ligand to the receptor. The predicted binding energy for
docked serotonin is found to beB7.25 kcal/mol. Docking of the
synthetic specific agonist, 8-OH-DPAT, with the receptor
resulted in slightly higher binding energy (B7.5 kcal/mol).
Synthetic ligands appear to bind to the receptor with higher
binding energy. In general, it appears that docked antagonists
exhibit higher binding energies compared to that of agonists.
Importantly, both agonists and antagonist show higher binding
Fig. 7 Chemical structures of antagonists for the serotonin1A receptor. Antagonists such as p-MPPF, WAY-100635, DWAY and NOWAY are
used to dock to the receptor.
Fig. 8 Model of the human serotonin1A receptor showing docked
sites and poses of serotonin (agonist) and WAY-100635 (antagonist).
Interestingly, the antagonist binding site is found to be relatively
shallow compared to the agonist binding site. Transmembrane helices
I–VII are shown in different colors. See the Experimental section for
other details.
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energies when docked to the receptor in the presence of
cholesterol. Our results therefore demonstrate that membrane
cholesterol facilitates ligand binding to the serotonin1A receptor.
Interestingly, we have previously shown that the affinity of
specific agonist (8-OH-DPAT)47 and antagonist (p-MPPF)48 to
the serotonin1A receptor is reduced upon cholesterol depletion.
Fig. 9 Representation of docked poses of agonists to the human serotonin1A receptor. Snapshots of interactions of the serotonin1A receptor with
various agonists from AutoDock are shown. Agonists include serotonin, 8-OH-DPAT and 5-CT.
Fig. 10 Representation of docked poses of antagonists to the human serotonin1A receptor. Snapshots of interactions of the serotonin1A receptor
with various antagonists from AutoDock are shown. Antagonists include p-MPPF, WAY-100635, DWAY and NOWAY.
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Discussion
Lipid–protein interactions play a crucial role in maintaining
the structure and function of integral membrane proteins and
receptors.49–52 A large portion of any given transmembrane
receptor remains in contact with the lipid environment. This
raises the obvious possibility that membrane lipids could be
important modulators of receptor structure and function.
Work from a number of groups has contributed to our
understanding of the requirement of specific lipids for
maintaining the proper topology, structure and function of
membrane proteins.49,50,53,54 Cholesterol is an essential and
representative lipid in higher eukaryotic cellular membranes.55,56
Importantly, cholesterol plays a vital role in the function and
organization of GPCRs.51,57 These effects of cholesterol on
GPCRs have been attributed either to specific interactions of
lipids with amino acids in proteins or to bulk properties of
membranes.58
In addition to the recently reported cholesterol-bound
crystal structure of the b2-adrenergic receptor,
17,21 the crystal
structure of a photo-stationary state, highly enriched in me-
tarhodopsin I, showed a cholesterol molecule between two
rhodopsin monomers.20 These authors also reported that
cholesterol could improve the reliability and yield of crystall-
ization. In this structure, cholesterol is shown to be oriented
with its tetracyclic ring aligned normal to the membrane
bilayer. These authors proposed that some of the tryptophans
in transmembrane helices would be able to interact with the
tetracyclic ring of cholesterol. Specific cholesterol interaction
(i.e., through a direct interaction that could induce a
conformational change in the receptor) has been shown for
GPCRs such as oxytocin57,59,60 and galanin61 receptors. In
addition, new information on lipid-mediated dimerization of
cannabinoid receptors has been obtained by homology
modeling using the crystal structure of b2-adrenergic
receptor.62 Interestingly, recent molecular dynamics simulations
have shown that membrane cholesterol specifically interacts
with transmembrane domains of GPCRs such as rhodopsin63
and human A2A adenosine receptor,
64 thereby stabilizing helix
II of the human A2A adenosine receptor. A consequence of this
interaction is that the receptor couples to G-proteins only in
the presence of cholesterol.
The overall objective of the present work is to generate and
validate a reliable homology model of the serotonin1A receptor
and use this model to dock well-characterized ligands to the
receptor and explore the role of cholesterol in ligand binding.
Although homology models of the serotonin1A receptor were
previously generated using rhodopsin as a template,65,66 our
work represents the first comprehensive model of the human
serotonin1A receptor generated using the human b2-adrenergic
receptor as a template. The success of homology modeling
Table 1 Analysis of the molecular interactions in docked posesa
Agonist
Interactions involving:
Hydrogen bonds Nonpolar residues Polar residues
Serotonin Asp116 Leu78 Asp82
Cys120 Val85
Ser123 Cys119
Gly389 Phe354
Ser393 Trp358
Tyr390
Asn392
8-OH-DPAT Ser190 Cys109 Asp110
Met172 Asp185
Trp175
Thr177
Pro178
Pro184
Ala186
Cys187
Thr188
Ile189
5-CT Asp116 Leu78 Asp82
Val85 Ser123
Cys119 Ser393
Cys120
Phe354
Trp358
Gly389
Tyr390
Asn392
a Residues that are reported to be involved in binding are in bold.
Table 2 Analysis of the molecular interactions in docked poses
Antagonist
Interactions involving:
Nonpolar residues Polar residues
p-MPPF Val117 Lys191
Cys120
Ile189
Thr196
Thr200
Ala203
Phe361
Phe362
Val364
Ala365
Leu368
WAY-100635 Thr188 Ser190
Ile189 Lys191
Tyr195 Ser199
Thr196
Thr200
Phe361
Leu368
Thr379
Gly382
DWAY Ile189 Lys191
Thr188 Ser373
Tyr195
Thr196
Ala365
Leu368
Phe361
Val364
Gly382
NOWAY Ile189 Glu372
Met172 Lys191
Phe361 Ser199
Ala365 Ser190
Thr200 Glu179
Tyr195
Thr196
Leu368
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often depends on the similarity of structural and functional
relationships between the template and the modeled protein.43,67
The quality and refinement of the model would improve with
availability of better templates. It is in this context that our
present model is more reliable since the sequence similarity
(B48%) between the human serotonin1A receptor and
human b2-adrenergic receptor in the transmembrane region is
considerably higher compared to the similarity (B38%) between
serotonin1A receptor and rhodopsin sequences.
Previous work from our laboratory has comprehensively
demonstrated the requirement of membrane cholesterol
in the function and organization of the serotonin1A
receptor.47,48,51,52,68,69 We have recently proposed that
membrane cholesterol could occupy ‘nonannular’ binding
site(s) on the receptor.22 Nonannular sites are characterized
by lack of accessibility to annular lipids, i.e., these sites cannot
be displaced by competition with annular lipids. In the present
work, we combined homology modeling with cholesterol-
specific conformations of the serotonin1A receptor. Our results
constitute an early attempt to incorporate cholesterol
specificity of GPCRs in homology modeling. In the context
of increasing pharmacological relevance of the serotonin1A
receptor, interaction of this transmembrane protein with
surrounding lipids (such as cholesterol) assumes greater
significance in its structure and function in healthy and
diseased states.
GPCRs are involved in a multitude of physiological
functions and represent important drug targets. Although
the pharmacological and signaling features of GPCRs have
been extensively studied, aspects related to their interaction
with membrane lipids have been addressed in very few cases.
In this context, the realization that lipids such as cholesterol
could influence the structure and function of GPCRs has
remarkably transformed our idea regarding the function of
this important class of membrane proteins. With progress in
deciphering molecular details on the nature of this interaction,
our overall understanding of GPCR function in health and
disease would improve significantly, thereby enhancing our
ability to design better therapeutic strategies to combat
diseases related to malfunctioning of these receptors. A
comprehensive understanding of GPCR function in relation
to the membrane lipid environment is important, in view of the
enormous implications of GPCR function in human health,7,8
and the observation that several diagnosed diseases are
attributed to altered lipid–protein interactions.70,71 We conclude
that homology modeling,12 in combination with emerging
knowledge of lipid specificities of GPCRs,52 represent a
promising approach to use in future drug discovery research.
Experimental section
Sequence analysis
All sequences used for the analysis, including the sequence
(BBA94488) of the human serotonin1A receptor, were obtained
from the NCBI (http://www.ncbi.nlm.nih.gov/) database.
Sequence alignment of the human serotonin1A receptor and
human b2-adrenergic receptor was carried out with ClustalX
(version 2.0.11). Sequence alignments were performed on sets
of receptor sequences to identify conserved residues that could
have structural and or functional implications. Sequence
alignments were carried out with all subtypes of the serotonin-1
receptor (A, B; D–F) and the serotonin1A receptor from
invertebrates and vertebrates. Alignments were constructed
using ClustalX and were manually-edited and viewed using
Jalview (version 2.4) to retain high equivalence of conserved
regions. Residues are numbered according to the human
serotonin1A receptor sequence throughout the text.
Homology modeling
The serotonin1A receptor and b2-adrenergic receptor are both
biogenic amine GPCRs, and enjoy a sequence similarity of
B48%. The human serotonin1A (BBA94488) and human
b2-adrenergic receptor (2RH1) sequences were aligned using
ClustalX and viewed and edited using Jalview. Recently
reported crystal structures of the human b2-adrenergic receptor
were obtained from RCSB (http://www.rcsb.org/pdb) and
used as templates. Accession numbers of the crystal structures
of human b2-adrenergic receptors in the absence and presence
of cholesterol are 2RH117 and 3D4S,21 respectively. We chose
3D4S as a template for modeling the human serotonin1A
receptor due to the presence of two cholesterol molecules in
the structure. The coordinates corresponding to 1–28 and
343–365 segments were not available in 2RH1, and coordinates
corresponding to 1–31 and 343–365 segments were not available
in 3D4S crystal structures due to poor electron density,
and therefore these residues were removed from the query
Fig. 11 Predicted binding energies of docked poses of (a) agonists
and (b) antagonists to the human serotonin1A receptor in the absence
and presence of cholesterol. Binding energies in the absence and
presence of cholesterol are shown as empty and filled bars,
respectively.
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sequence prior to alignment. The final alignment was used to
construct the model using the software Modeller72
(version 9.7). A set of 200 models was generated, from which
the lowest energy structure was used for further processing.
The initial low energy model obtained from Modeller was
validated by using PROCHECK73 and WHAT IF74 servers.
We have also analyzed the side chain orientation of conserved
residues (which are conserved at least in all class-A GPCR
sequences), by superposing our model against the available
crystal structures (2RH1 and 3D4S) in order to analyze the
goodness of fit with other structures. We focused mostly on
the modeling of the transmembrane helical bundle.
Docking study
We carried out blind docking using AutoDock (version 4.0).
Blind docking is often used assuming that the ligand binding
site is unknown and the structures of the ligand and the
receptor are known. In our case, it would be necessary to
perform dockings to search the entire surface of the receptor.
This was achieved using AutoGrid to create grid maps, with
40 points in each dimension, and creating sets of adjacent grid
map volumes that cover the entire transmembrane region of
the receptor. Rigid protein-flexible ligand docking of seven
different ligands, including agonists and antagonists, was
carried out with AutoDock. The agonists include serotonin
(natural ligand) and 8-OH-DPAT, and antagonists are
p-MPPF and WAY-100635. The AutoDock graphical
interface AutoDockTools was used to keep polar hydrogen
atoms and add partial charges for protein using the Gasteiger
charges. The grid maps were calculated using the auxiliary
program Autogrid 4.0. Blind docking was performed using a
grid box of 40  40  40 cells (each cell has dimensions
0.375  0.375  0.375 A˚) by moving it around to cover the
entire transmembrane region. The Lamarckian genetic
algorithm (LGA) was selected for ligand conformational
searching. Docking was carried out with a population size of
150 with 25  105 evaluations and a maximum of 27 000
generations. Conformations were analyzed using the MGL
AutoDock tools (version 1.5.2). Chemical structures of ligands
were obtained from PubChem and three dimensional
structures of ligands were generated using Open Babel
(version 2.2.3).
Molecular dynamics simulations of receptor models
Molecular dynamics simulations were performed to validate
homology models of the serotonin1A receptor in the absence
and presence of cholesterol. Systems were represented using
the MARTINI coarse-grain force-field (version 2.1).75,76
Models were mapped to their coarse-grain representations.
The receptor model in the absence of cholesterol was simulated
in a pure POPC membrane containing 200 lipid molecules and
the receptor model in the presence of cholesterol was simulated in
a POPC–cholesterol mixed bilayer containing 80 cholesterol
and 80 POPC molecules. Simulations were performed using
the GROMACS program package (version 4.0.2),77 with the
scheme developed for coarse-grain simulations, under periodic
boundary conditions. Temperature was weakly coupled (coupling
time 0.1 ps) to a thermostat at 300 K using the Berendsen
algorithm.78 Pressure was weakly coupled (coupling time
1.0 ps, compressibility 5  105 bar) using a semi-isotropic
coupling scheme, in which the lateral and perpendicular
pressures are coupled independently at 1 bar. Non-bonded
interactions were treated with a switch function from 0–1.2 nm
for Coulomb interactions and 0.9–1.2 nm for LJ interactions
(pair-list update frequency of once per 10 steps). A time step of
25 fs was used.
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